These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

659 related items for PubMed ID: 12534334

  • 1. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.
    Easton J, Noble S, Perry CM.
    Drugs; 2003; 63(3):311-40. PubMed ID: 12534334
    [Abstract] [Full Text] [Related]

  • 2. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 3. Amoxicillin/clavulanate for infections in infants and children: past, present and future.
    Klein JO.
    Pediatr Infect Dis J; 2003 Aug; 22(8 Suppl):S139-48. PubMed ID: 14567000
    [Abstract] [Full Text] [Related]

  • 4. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children.
    Hoberman A, Dagan R, Leibovitz E, Rosenblut A, Johnson CE, Huff A, Bandekar R, Wynne B.
    Pediatr Infect Dis J; 2005 Jun; 24(6):525-32. PubMed ID: 15933563
    [Abstract] [Full Text] [Related]

  • 5. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children.
    Piglansky L, Leibovitz E, Raiz S, Greenberg D, Press J, Leiberman A, Dagan R.
    Pediatr Infect Dis J; 2003 May; 22(5):405-13. PubMed ID: 12792379
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora.
    Cohen R, Navel M, Grunberg J, Boucherat M, Geslin P, Derriennic M, Pichon F, Goehrs JM.
    Pediatr Infect Dis J; 1999 May; 18(5):403-9. PubMed ID: 10353511
    [Abstract] [Full Text] [Related]

  • 10. [Antibiotic management of acute otitis media. New recommendations].
    Longuet P.
    Presse Med; 2000 Dec 02; 29(37):2049-50. PubMed ID: 11155733
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM, Scott LJ.
    Drugs; 2004 Dec 02; 64(13):1433-64. PubMed ID: 15212560
    [Abstract] [Full Text] [Related]

  • 14. Microbiology of acute otitis media recently treated with aminopenicillins.
    Block SL, Hedrick JA, Tyler RD, Smith RA, Harrison CJ.
    Pediatr Infect Dis J; 2001 Nov 02; 20(11):1017-21. PubMed ID: 11734704
    [Abstract] [Full Text] [Related]

  • 15. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
    Berry V, Hoover J, Singley C, Woodnutt G.
    Antimicrob Agents Chemother; 2005 Mar 02; 49(3):908-15. PubMed ID: 15728883
    [Abstract] [Full Text] [Related]

  • 16. Treatment of acute otitis media consensus recommendations.
    Hoberman A, Marchant CD, Kaplan SL, Feldman S.
    Clin Pediatr (Phila); 2002 Mar 02; 41(6):373-90. PubMed ID: 12166789
    [Abstract] [Full Text] [Related]

  • 17. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
    File TM, Jacobs MR, Poole MD, Wynne B, 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups.
    Int J Antimicrob Agents; 2002 Oct 02; 20(4):235-47. PubMed ID: 12385678
    [Abstract] [Full Text] [Related]

  • 18. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML, García Y, Valero E, Amores R, Fuentes F.
    Rev Esp Quimioter; 2000 Sep 02; 13(3):306-13. PubMed ID: 11086282
    [Abstract] [Full Text] [Related]

  • 19. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media.
    Arguedas A, Emparanza P, Schwartz RH, Soley C, Guevara S, de Caprariis PJ, Espinoza G.
    Pediatr Infect Dis J; 2005 Feb 02; 24(2):153-61. PubMed ID: 15702045
    [Abstract] [Full Text] [Related]

  • 20. Bacteriologic failure of amoxicillin-clavulanate in treatment of acute otitis media caused by nontypeable Haemophilus influenzae.
    Patel JA, Reisner B, Vizirinia N, Owen M, Chonmaitree T, Howie V.
    J Pediatr; 1995 May 02; 126(5 Pt 1):799-806. PubMed ID: 7752010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.